Mirum Pharmaceuticals, Inc. et al v. Zenara Pharma Private Limited et al
| Mirum Pharmaceuticals, Inc., Satiogen Pharmaceuticals, Inc. and Shire Human Genetic Therapies, Inc. |
| Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Limited |
| 1:2026cv01154 |
| September 14, 2026 |
| U.S. District Court for the District of Delaware |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on September 15, 2026. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 7 Alias Summons issued as to Biophore India Pharmaceuticals Private Limited, Zenara Pharma Private Limited. (Attachments: #1 Alias Summons Issued)(mpb) |
| Filing 6 Summons Issued as to Biophore India Pharmaceuticals Private Limited on 9/15/2026; Zenara Pharma Private Limited on 9/15/2026. (Attachments: #1 Summons Issued)(mpb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mirum Pharmaceuticals, Inc. for Satiogen Pharmaceuticals, Inc.; Corporate Parent Takeda Pharmaceuticals U.S.A., Inc., Other Affiliates Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals International AG, and the Master Trust Bank of Japan, Ltd. for Shire Human Genetic Therapies, Inc. - filed by Mirum Pharmaceuticals, Inc., Satiogen Pharmaceuticals, Inc., Shire Human Genetic Therapies, Inc. (mpb) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,512,657 B2; US 11,229,661 B2; US 12,350,267 B2; US 11,229,647 B2 ; US 11,376,251 B2; US 11,497,745 B2 ; US 12,296,050 B2; US 11,260,053 B2. (mpb) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/6/2026. Date of Expiration of Patent: 10/26/2032 for US 10,512,657 B2, US 11,229,661 B2, US 12,350,267 B2, and US 11,376,251 B2; 2/12/2040 for US 11,229,647 B2 and US 11,497,745 B2; 5/26/2031 for US 11,260,053 B2; 10/5/2043 for US 12,296,050 B2.Thirty Month Stay Deadline: 3/29/2029. (mpb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Filing 1 COMPLAINT against Biophore India Pharmaceuticals Private Limited, Zenara Pharma Private Limited (Filing fee $ 405, receipt number ADEDC-5064959) - filed by Mirum Pharmaceuticals, Inc., Satiogen Pharmaceuticals, Inc., Shire Human Genetic Therapies, Inc. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit G, #8 Exhibit H, #9 Civil Cover Sheet)(mpb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the U.S. Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
